The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of patients with human epidermal growth factor 2 (HER2)–positive breast cancer receiving neoadjuvant therapy without adjuvant ado-trastuzumab emtansine (T-DM1).
 
Massimo Di Iorio
No Relationships to Disclose
 
Mitchell J. Elliott
No Relationships to Disclose
 
Jordan L Scott
No Relationships to Disclose
 
Abhenil Mittal
No Relationships to Disclose
 
Consolacion Molto
No Relationships to Disclose
 
Faris Tamimi
No Relationships to Disclose
 
David W. Cescon
Consulting or Advisory Role - AstraZeneca; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Merck; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene.
 
Eitan Amir
Honoraria - Exact Sciences; Novartis; Sandoz
 
Nicholas Meti
Honoraria - Takeda